[Pfizer Inc.](https://www.pfizer.com)

May 5, 2026 (Submission deadline – full application due)

Up to $250,000 for one project; maximum project length 1 year

Supports development and validation of a shared decision-making tool to improve outcomes for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

--- ## Description This grant opportunity, offered by Pfizer Inc., aims to support U.S.-based medical societies or professional organizations (in partnership with patient advocacy organizations) in the development, validation, and/or evaluation of a shared decision-making (SDM) tool for individuals living with transthyretin amyloid cardiomyopathy (ATTR-CM). The initiative targets improvement of decision quality, health outcomes, patient experience, and overall quality of care by addressing diagnostic delays, complex treatment pathways, and decisional conflict through patient-centered, evidence-based approaches. Proposals should emphasize: - Tool design based on decision-making theory and SDM methodology - Co-development with stakeholders (patients, advocacy groups, clinicians) - Comprehensive needs assessment and conceptual framework - Validation and usability testing with end-users Drug compound provision or development is explicitly out of scope. --- ## Due Dates - May 5, 2026: Submission deadline (full application due) Other key dates: - Anticipated grant award notification: June 19, 2026 - Anticipated project start: September 2026 - Anticipated project end: September 2027 --- ## Funding Amount - Only one individual project will be funded, with a maximum award of $250,000 (USD). - Project duration: up to 1 year. - Award includes direct costs, institutional overhead (capped at 28%), and indirect costs. - Funds are distributed via milestone payments tied to deliverables, such as project kickoff, patient advocacy group onboarding, tool drafts, validation results, and final tool dissemination. --- ## Eligibility - **Geographic scope:** United States - **Eligible applicants:** - Medical societies or professional organizations, in partnership with patient advocacy organizations, focusing on ATTR-CM. - Only organizations may apply; individuals or unaffiliated medical practice groups are not eligible. - The principal investigator (PI) must: - Hold a medical or postdoctoral degree (MD, PhD, or equivalent), advanced nursing degree (BSN with MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work. - Be an employee or contractor of the applicant organization. - Be based in the United States. - The applicant organization must be legally able to receive funding directly from Pfizer Inc. - **Collaborative projects:** Permitted if all organizations have relevant roles and the lead organization is central to the project. --- ## Application Process - Applications must be submitted online via [www.cybergrants.com/pfizer/Research](http://www.cybergrants.com/pfizer/Research). - Select "Start A New Research Grant Application" and follow the instructions. - Indicate "Competitive Grant?": Yes - Primary Area of Interest: CVM - ATTR-CM (Transthyretin Amyloid Cardiomyopathy) - RES - Competitive Grant Program Name: 2026 RD US CVM ATTR-CM SDM RES - Upload a full proposal (max 15 pages, single-spaced, Calibri 12-point font, 1-inch margins) addressing: - Goals and objectives - Assessment of need - Target audience - Project design and methods - Innovation and originality - Evaluation and outcomes - Timeline - Organization and budget details - Required documents: project plan/proposal, initial study protocol, IRB/IEC approval - Proposals must be received by 23:59 EST on May 5, 2026. --- ## Additional Information - Applications submitted after the deadline will not be reviewed. - Pfizer will not fund capital purchases (e.g., equipment, software licenses, infrastructure). - Overhead is capped at 28%; general organizational running costs must be included as overhead, not as line items. - The PI must not submit a grant for a study that has already commenced without prior Pfizer support. - Grant agreements are non-negotiable except for legal conflicts. --- ## External Links - [Full RFP and program details (PDF)](https://cdn.pfizer.com/pfizercom/2026-03/2026-RD-US-CVM-ATTR-CM-SDM-RES.pdf?VersionId=S8xl9MIKd2jCnM0E4OqFRuihmBnLmLGS) - [Pfizer Research Grants Portal](http://www.cybergrants.com/pfizer/Research) - [Pfizer Inc. main page](https://www.pfizer.com) --- ## Contact Information | Role | Name | Email | Phone | |---------------------|-----------------------------|-----------------------------------------------------|------------------| | Grant Officer | Talita Honorato-Rzeszewicz | [talita.honorato-rzeszewicz@pfizer.com](mailto:talita.honorato-rzeszewicz@pfizer.com) | 1-800-879-3477 | | General Contact | Pfizer Inc. | [Contact form](https://www.pfizer.com/contact) | 1-800-879-3477 |

Pfizer Research Grant Request for Proposals: Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool

Sign in to see full grant listing